BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,140,629 | -19.9% | 119,611 | -4.5% | 0.04% | -16.3% |
| Q2 2023 | $10,165,109 | +110.3% | 125,248 | +92.2% | 0.04% | +95.5% |
| Q1 2023 | $4,834,591 | -11.0% | 65,165 | +1.3% | 0.02% | -15.4% |
| Q4 2022 | $5,429,363 | +19.1% | 64,323 | +300.7% | 0.03% | +13.0% |
| Q3 2022 | $4,559,000 | -17.1% | 16,054 | +1.2% | 0.02% | -11.5% |
| Q2 2022 | $5,498,000 | -22.1% | 15,861 | -2.7% | 0.03% | -7.1% |
| Q1 2022 | $7,057,000 | -14.9% | 16,297 | -1.2% | 0.03% | -3.4% |
| Q4 2021 | $8,297,000 | +1.2% | 16,495 | -2.5% | 0.03% | -6.5% |
| Q3 2021 | $8,196,000 | +7.2% | 16,914 | -0.4% | 0.03% | +10.7% |
| Q2 2021 | $7,643,000 | +58692.3% | 16,975 | +31928.3% | 0.03% | – |
| Q3 2020 | $13,000 | -7.1% | 53 | 0.0% | 0.00% | – |
| Q2 2020 | $14,000 | +40.0% | 53 | 0.0% | 0.00% | – |
| Q1 2020 | $10,000 | -16.7% | 53 | 0.0% | 0.00% | – |
| Q4 2019 | $12,000 | +20.0% | 53 | 0.0% | 0.00% | – |
| Q3 2019 | $10,000 | -9.1% | 53 | 0.0% | 0.00% | – |
| Q2 2019 | $11,000 | 0.0% | 53 | 0.0% | 0.00% | – |
| Q1 2019 | $11,000 | -96.2% | 53 | -97.4% | 0.00% | -100.0% |
| Q4 2018 | $290,000 | -91.9% | 2,053 | -88.3% | 0.00% | -85.7% |
| Q3 2018 | $3,569,000 | -47.8% | 17,508 | -62.3% | 0.01% | -53.3% |
| Q2 2018 | $6,831,000 | +44.9% | 46,392 | +48.7% | 0.02% | +36.4% |
| Q1 2018 | $4,713,000 | +73.6% | 31,205 | +24.4% | 0.01% | -72.5% |
| Q3 2016 | $2,715,000 | -9.5% | 25,079 | -8.9% | 0.04% | -11.1% |
| Q2 2016 | $3,001,000 | +28.7% | 27,542 | +12.9% | 0.04% | +32.4% |
| Q1 2016 | $2,331,000 | +10.7% | 24,398 | +6.4% | 0.03% | +9.7% |
| Q4 2015 | $2,106,000 | -22.6% | 22,935 | -23.5% | 0.03% | -24.4% |
| Q3 2015 | $2,722,000 | -20.4% | 29,970 | -14.0% | 0.04% | -12.8% |
| Q2 2015 | $3,418,000 | -17.3% | 34,842 | -15.2% | 0.05% | -7.8% |
| Q1 2015 | $4,135,000 | +1.0% | 41,092 | -5.5% | 0.05% | -3.8% |
| Q4 2014 | $4,094,000 | – | 43,502 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |